NLRP3 inhib 
Welcome,         Profile    Billing    Logout  
 7 Companies  6 Products   6 Products   29 Diseases   11 Trials   763 News 


«12...678910111213141516...134135»
  • ||||||||||  Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
    Journal:  Potassium ion efflux induces exaggerated mitochondrial damage and non-pyroptotic necrosis when energy metabolism is blocked. (Pubmed Central) -  Jan 24, 2024   
    Furthermore, fructose 1,6-bisphosphate, a high-energy intermediate of glycolysis, significantly suppressed CPI-613+nigericin-induced mitochondrial damage and cell death. Collectively, our data show that energy deficiency diverts NLRP3 inflammasome activation-dependent pyroptosis to Nlrp3-independent necrosis upon K efflux inducers, which can be dampened by high-energy intermediate, highlighting a critical role of energy metabolism in cell survival and death under inflammatory conditions.
  • ||||||||||  chloroquine phosphate / Generic mfg., alendronate / Generic mfg.
    Preclinical, Journal:  Quercetin suppresses ovariectomy-induced osteoporosis in rat mandibles by regulating autophagy and the NLRP3 pathway. (Pubmed Central) -  Jan 23, 2024   
    (IL-1?) and interleukin-18 (IL-18) on the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) protein 3 (NLRP3) pathway thereby inhibiting osteoclast differentiation, immunofluorescence and western blotting also confirmed that QR inhibited autophagy in OVX rats and suppressed the number of tartrate-resistant acid phosphatase (TRAP)-stained positive osteoclasts. The findings suggest that QR may protect the bone structure and prevent bone loss in osteoporotic rats by inhibiting the NLRP3 pathway and autophagy in osteoclasts with comparable effects to ALN, thus QR may have the potential to be a promising alternative supplement for the preventive and therapeutic treatment of PMOP.
  • ||||||||||  Journal:  Splenectomy ameliorates liver cirrhosis by restoring the gut microbiota balance. (Pubmed Central) -  Jan 16, 2024   
    Moreover, we have investigated apoptosis and mitophagy-inducing compounds from this plant extract having anticancer activity against oral cancer cells. SP-mediated gut microbiota regulation ameliorates ConA-related LC progression by inhibiting Tlr4/Nlrp3 in the liver.
  • ||||||||||  Preclinical, Journal:  6,7-Dimethoxycoumarin, Gardenoside and Rhein combination improves non-alcoholic fatty liver disease in rats. (Pubmed Central) -  Jan 15, 2024   
    In the non-alcoholic fatty liver disease (NAFLD) rat model, the concurrent administration of three-component DGR effectively regulated lipid deposition, suppressed liver inflammation, and restored balance in the intestinal flora, thereby improving NAFLD pathology. These findings propose a promising therapeutic strategy for NAFLD, centered on inhibiting the NLRP3 inflammasome through the use of the three-component DGR.
  • ||||||||||  Preclinical, Journal:  Bone Marrow Mesenchymal Stem Cells Alleviate Acute Severe Pancreatitis and Promote Lung Repair via Inhibiting NLRP3 Inflammasome in Rat. (Pubmed Central) -  Jan 15, 2024   
    Overall, malvidin alleviated lipopolysaccharide-induced sepsis AKI, improved mitochondrial function and mitochondrial biogenesis, and inhibited the NLRP3 inflammasome through the PGC-1?/Nrf2 signaling pathway, suggesting that malvidin might translate into clinical applications for sepsis AKI therapy. The therapeutic effect of BMSC on SAP is at least partially ascribed to the inhibition of NLRP3 inflammasome, and Nrf2 pathway mediates the therapeutic effect of BMSC on SAP by inhibiting NLRP3 inflammasome.
  • ||||||||||  Journal:  Nuclear receptor coactivator 6 is a critical regulator of NLRP3 inflammasome activation and gouty arthritis. (Pubmed Central) -  Jan 10, 2024   
    Consistent with these findings, NCOA6 was highly expressed in macrophages derived from gout patients, and NCOA6-positive macrophages were significantly enriched in gout macrophages according to the transcriptome profiling results. Conclusively, NCOA6 is a critical regulator of NLRP3 inflammasome activation and is therefore a promising target for NLRP3-dependent diseases, including gout.
  • ||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
    Journal:  Identification of Azalamellarin N as a Pyroptosis Inhibitor. (Pubmed Central) -  Jan 8, 2024   
    From our original compound library, we identified azalamellarin N (AZL-N), a hexacyclic pyrrole alkaloid, as an inhibitor of pyroptosis induced by R837 (also called imiquimod), which is an agonist of the intracellular multiprotein complex nucleotide-binding and oligomerization domain-like receptor (NLR) family pyrin domain containing 3 (NLRP3) inflammasome...These results suggest that AZL-N inhibits pyroptosis by targeting molecule(s), which may be protein kinase(s), that act upstream of NLRP3 inflammasome activation, rather than by directly targeting the components of the NLRP3 inflammasome. Further identification and analysis of target molecule(s) of AZL-N will shed light on the regulatory mechanisms of pyroptosis, particularly those depending on proinflammatory stimuli.
  • ||||||||||  amitriptyline / Generic mfg.
    Amitriptyline inhibits Nlrp3 inflammasomes Activation Via Suppressing The Asm/Ce Pathway in NAFLD (Room 15, J) -  Jan 6, 2024 - Abstract #APASL2024APASL_695;    
    ASM / CE-NLRP3 inflammasome pathway is a pivotal mechanism of hepatocyte steatosis, inflammation, and cell damage in NAFLD. Amitriptyline can inhibit this pathway from the source and exert the anti-lipid deposition and anti-inflammatory effects, suggesting that ASM/CE-NLRP3 pathway is a key target in the treatment of NAFLD.
  • ||||||||||  Journal:  Potential Impact of Bioactive Compounds as NLRP3 Inflammasome Inhibitors: An Update. (Pubmed Central) -  Jan 4, 2024   
    We conducted an in-depth research review by searching for relevant articles in the Scopus, Google Scholar, and PubMed databases. By gathering information on phytochemical inhibitors that block NLRP3 inflammasome activation, a complicated balance between inflammasome activation or inhibition with NLRP3 as a key role was revealed in NLRP3-driven clinical situations.
  • ||||||||||  Journal:  Bile acids induce liver fibrosis through the NLRP3 inflammasome pathway and the mechanism of FXR inhibition of NLRP3 activation. (Pubmed Central) -  Jan 4, 2024   
    By gathering information on phytochemical inhibitors that block NLRP3 inflammasome activation, a complicated balance between inflammasome activation or inhibition with NLRP3 as a key role was revealed in NLRP3-driven clinical situations. (1) Primary conjugated bile acids increased in patients with liver fibrosis; (2) GCDCA induce hepatic fibrosis via the NLRP3 inflammasome pathway; (3) FXR inhibits NLRP3 activity by restraining its phosphorylation; (4) knockdown or knockout of NLRP3 may relieve the onset of hepatic fibrosis.
  • ||||||||||  Preclinical, Journal:  Naja naja snake venom-induced local toxicities in mice is by inflammasome activation. (Pubmed Central) -  Jan 3, 2024   
    In conclusion, the present data showed that inflammasome is one of the host responses involved in N. naja snake venom-induced toxicities. The inhibition of inflammasome activation will provide new insight into better management of snake bite-induced local tissue damage.
  • ||||||||||  Journal:  Fibroblastic reticular cell-derived exosomes are a promising therapeutic approach for septic acute kidney injury. (Pubmed Central) -  Jan 3, 2024   
    Compared with an equivalent dose of recombinant CD5L, the modified CD5L-enriched FRC-Exos selectively bound PKTCs, promoted kinase PINK-ubiquitin ligase PARKIN-mediated mitophagy, inhibiting pyroptosis and improved kidney function by hindering NLRP3 inflammasome activation, thereby improving the sepsis survival rate. Thus, strategies to modify FRC-Exos could be a new avenue in developing therapeutics against kidney injury.
  • ||||||||||  Journal:  Total glucosides of paeony alleviates experimental Sj (Pubmed Central) -  Dec 31, 2023   
    Collectively, our results indicated that TGP alleviates SS through inhibition of the activation of NLRP3 inflammasome of SG. These findings clarified the mechanism underlying the therapeutic effects of TGP on SS, and provided new evidence for the further application of TGP in the treatment of SS.
  • ||||||||||  Review, Journal:  Food-derived peptides as novel therapeutic strategies for NLRP3 inflammasome-related diseases: a systematic review. (Pubmed Central) -  Dec 28, 2023   
    Finally, the progress of cutting-edge technologies, including nanoparticle, computer-aided screening strategy and recombinant DNA technology, in the acquisition or encapsulation of NLRP3 inhibitory FDBP was discussed. This review provides a scientific basis for understanding the anti-inflammatory mechanism of FDBP through the regulation of the NLRP3 inflammasome and also provides guidance for the development of therapeutic adjuvants or functional foods enriched with these FDBP.